神经元来源细胞外囊泡α-突触核蛋白作为帕金森病发病风险个体的血清生物标志物
本回顾性横断面多中心研究纳入576名参与者,评估血清神经元来源细胞外囊泡(L1EV)α-突触核蛋白对帕金森病(PD)前驱期的识别能力。结果显示,该标志物可区分特发性快速眼动睡眠行为障碍(iRBD)与对照(AUC=0.91;95%CI,0.86-0.96),并区分前驱期PD概率>80%与<5%的个体(AUC=0.80;95%CI,0.71-0.89)。作者认为L1EV α-突触核蛋白联合前驱期标志物应考虑用于高危人群分层。
要点
- 血清L1EV α-突触核蛋白区分iRBD与对照的AUC=0.91(95%CI,0.86-0.96)。
- 区分前驱期PD概率>80%与<5%的AUC=0.80(95%CI,0.71-0.89)。
- 在转化为PD或相关痴呆的病例中,80%(n=40)超过所确定的阈值。
核心结论
- L1EV α-突触核蛋白联合前驱期标志物应考虑用于高危发展为PD及相关路易体病个体的分层。
研究设计与样本
- 回顾性、横断面多中心研究,纳入牛津发现队列、马尔堡队列、科隆队列和帕金森病进展标志物计划队列,共576名参与者。
主要发现
- 推导组中血清L1EV α-突触核蛋白阈值区分iRBD与对照的AUC=0.91(95%CI,0.86-0.96)。
- 区分前驱期PD概率>80%与<5%的AUC=0.80(95%CI,0.71-0.89)。
- 在所有队列中,区分前驱期PD概率>80%与当前及历史健康对照的AUC=0.90(95%CI,0.87-0.93)。
- 脑脊液种子扩增试验阳性的高危参与者L1EV α-突触核蛋白升高。
- 转化为PD或相关痴呆的病例中80%(n=40)超过所确定的阈值。
关键数值与推荐
- 前驱期PD概率依据更新版国际运动障碍学会研究标准判定。
临床怎么用
- 作者认为L1EV α-突触核蛋白联合前驱期标志物应考虑用于高危发展为PD及相关路易体病个体的分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nonmotor symptoms of Parkinson disease (PD) often predate the movement disorder by decades. Currently, there is no blood biomarker to define this prodromal phase. OBJECTIVE: To investigate whether α-synuclein in neuronally derived serum-extracellular vesicles identifies individuals at risk of developing PD and related dementia. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, cross-sectional multicenter study of serum samples included the Oxford Discovery, Marburg, Cologne, and Parkinson's Progression Markers Initiative cohorts. Participants were recruited from July 2013 through August 2023 and samples were analyzed from April 2022 through September 2023. The derivation group (n = 170) included participants with isolated rapid eye movement sleep behavior disorder (iRBD) and controls. Two validation groups were used: the first (n = 122) included participants with iRBD and controls and the second (n = 263) included nonmanifest GBA1N409S gene carriers, participants with iRBD or hyposmia, and available dopamine transporter single-photon emission computed tomography, healthy controls, and patients with sporadic PD. Overall the study included 199 participants with iRBD, 20 hyposmic participants with available dopamine transporter single-photon emission computed tomography, 146 nonmanifest GBA1N409S gene carriers, 21 GBA1N409S gene carrier patients with PD, 50 patients with sporadic PD, and 140 healthy controls. In the derivation group and validation group 1, participants with polysomnographically confirmed iRBD were included. In the validation group 2, at-risk participants with available Movement Disorder Society prodromal markers and serum samples were included. Among 580 potential participants, 4 were excluded due to alternative diagnoses. EXPOSURES: Clinical assessments, imaging, and serum collection. MAIN OUTCOME AND MEASURES: L1CAM-positive extracellular vesicles (L1EV) were immunocaptured from serum. α-Synuclein and syntenin-1 were measured by electrochemiluminescence. Area under the receiver operating characteristic (ROC) curve (AUC) with 95% CIs evaluated biomarker performance. Probable prodromal PD was determined using the updated Movement Disorder Society research criteria. Multiple linear regression models assessed the association between L1EV α-synuclein and prodromal markers. RESULTS: Among 576 participants included, the mean (SD) age was 64.30 (8.27) years, 394 were male (68.4%), and 182 were female (31.6%). A derived threshold of serum L1EV α-synuclein distinguished participants with iRBD from controls (AUC = 0.91; 95% CI, 0.86-0.96) and those with more than 80% probability of having prodromal PD from participants with less than 5% probability (AUC = 0.80; 95% CI, 0.71-0.89). Subgroup analyses revealed that specific combinations of prodromal markers were associated with increased L1EV α-synuclein levels. Across all cohorts, L1EV α-synuclein differentiated participants with more than 80% probability of having prodromal PD from current and historic healthy control populations (AUC = 0.90; 95% CI, 0.87-0.93), irrespective of initial diagnosis. L1EV α-synuclein was increased in at-risk participants with a positive cerebrospinal fluid seed amplification assay and was above the identified threshold in 80% of cases (n = 40) that phenoconverted to PD or related dementia. CONCLUSIONS AND RELEVANCE: L1EV α-synuclein in combination with prodromal markers should be considered in the stratification of those at high risk of developing PD and related Lewy body diseases.
引用
- Yan S, Jiang C, Janzen A, et al. Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease. JAMA Neurol. 2024. PMID: 38048087. doi:10.1001/jamaneurol.2023.4398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。